Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma
| Autor: | Damian J. Green, Pamela S. Becker, Edward N. Libby, Leona Holmberg |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Melphalan Male medicine.medical_specialty Combination therapy Nausea Gastrointestinal Diseases Transplantation Autologous Disease-Free Survival Drug Administration Schedule BV Regimen Bortezomib Maintenance therapy Internal medicine medicine Humans Multiple myeloma Lenalidomide Vorinostat business.industry Hematopoietic Stem Cell Transplantation Hematology General Medicine medicine.disease Survival Rate Treatment Outcome Female medicine.symptom business Multiple Myeloma medicine.drug |
| Zdroj: | Acta haematologica. 143(2) |
| ISSN: | 1421-9662 |
| Popis: | Background: In multiple myeloma (MM), relapse is a frequent complication after autologous hematopoietic stem cell transplant (ASCT). To reduce the risk of relapse, additional therapy has been added post-ASCT. In a nontransplant relapse setting, the combination of intravenous bortezomib and oral vorinostat (BV) was studied and showed efficacy. Therefore, it was reasonable to study this combination therapy post-ASCT. Patients and Methods: We report on BV given post-ASCT. All 30 patients underwent conditioning for ASCT with high-dose melphalan. After recovery from the acute transplant-related toxicity, BV therapy was started and given for a total of 12 (28-day) cycles. Results: The most common toxicities were hematological, gastrointestinal (diarrhea and nausea), fatigue, and peripheral neuropathy. The median follow-up for BV patients is 7.8 (range: 6.12–9.03) years. After BV therapy, 18 patients (60%) are alive, and 9 (30%) are alive without disease progression. Conclusions: BV can be given post-ASCT with an acceptable toxicity profile and produces reasonable disease-free and overall survival rates. A randomized study comparing the BV regimen to single-agent lenalidomide or bortezomib is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|